RATIONALE 303: A randomized phase 3 trial in nearly 792 patients with 2L, locally advanced or metastatic NSCLC (Squamous or Non-squamous)
Key Efficacy Outcome: mPFS
3.7x more patients treated with Etapidi versus docetaxel were progression-free at 12 months1
Key Efficacy Outcome: ORR & mDOR
Etapidi improved the overall response rate and disease control
rate versus docetaxel
1,2
Explore Clinical Safety
Access detailed safety and tolerability information to support treatment considerations in 2L NSCLC.
Tislelizumab Versus .Docetaxel in Patients with Previously Treated Advanced NSCLC (RATIONALE-303): A Phase 3, Open-Label, Randomized Controlled Trial
Reference: 1. SUPPLEMENTAL APPENDIX RATIONALE-303 : Zhou, Caicun et al. Journal of Thoracic Oncology, 2023, Volume 18, Issue 1, 93 – 106. 2.Zhou, Caicun et al. Journal of Thoracic Oncology, 2023, Volume 18, Issue 1, 93 – 106. 2. SUPPLEMENTAL APPENDIX RATIONALE-303 : Zhou, Caicun et al. Journal of Thoracic Oncology, 2023, Volume 18, Issue 1, 93 – 106